Product Portfolio

AP103 (Gene therapy)

In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB.  This gene-therapy platform also has potential applicability across a range of other genetic disorders.

Click here for more information
Our Science